[go: up one dir, main page]

MX2020008925A - Composicion oftalmica que comprende dicuafosol y polimero cationico. - Google Patents

Composicion oftalmica que comprende dicuafosol y polimero cationico.

Info

Publication number
MX2020008925A
MX2020008925A MX2020008925A MX2020008925A MX2020008925A MX 2020008925 A MX2020008925 A MX 2020008925A MX 2020008925 A MX2020008925 A MX 2020008925A MX 2020008925 A MX2020008925 A MX 2020008925A MX 2020008925 A MX2020008925 A MX 2020008925A
Authority
MX
Mexico
Prior art keywords
cationic
copolymers
hydrolyzed
diquafosol
cationic polymer
Prior art date
Application number
MX2020008925A
Other languages
English (en)
Inventor
Asuka Kamimura
Kenichi Endo
Kyohei Takahashi
Hiroyuki Asada
Kenji Morishima
Yusuke Momokawa
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MX2020008925A publication Critical patent/MX2020008925A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se proporciona una composición oftálmica que comprende dicuafosol o una sal del mismo y un polímero catiónico, siendo el polímero catiónico al menos uno seleccionado del grupo que consiste de quitosan, un derivado de quitosan, un copolímero de (met)acrilato catiónico, un polímero de silicona catiónica, un copolímero de sal de amonio cuaternario de dialiloacrilamida, queratina hidrolizada catiónica, seda hidrolizada catiónica, colágeno hidrolizado catiónico, caseína hidrolizada catiónica, proteína de soja hidrolizada catiónica, un copolímero de vinilpirrolidona catiónica, polivinilpirrolidona, un homopolímero de cloruro de dimetildiacrilamonio, un copolímero de ácido adípico-dimetilaminoh idroxipropildietilentriamina, un copolímero de ácido adípico-epoxipropildietilentriamina y un copolímero de sulfato de acrilamida-?-metacriloiloxietiltrimetil-amoniometilo.
MX2020008925A 2018-02-28 2019-02-27 Composicion oftalmica que comprende dicuafosol y polimero cationico. MX2020008925A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018035578 2018-02-28
PCT/JP2019/007542 WO2019168023A1 (ja) 2018-02-28 2019-02-27 ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物

Publications (1)

Publication Number Publication Date
MX2020008925A true MX2020008925A (es) 2020-10-01

Family

ID=67806273

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008925A MX2020008925A (es) 2018-02-28 2019-02-27 Composicion oftalmica que comprende dicuafosol y polimero cationico.
MX2022014791A MX2022014791A (es) 2018-02-28 2020-08-26 Composicion oftalmica que comprende dicuafosol y polimero cationico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014791A MX2022014791A (es) 2018-02-28 2020-08-26 Composicion oftalmica que comprende dicuafosol y polimero cationico.

Country Status (14)

Country Link
US (1) US20210000844A1 (es)
EP (1) EP3760207A4 (es)
JP (4) JP6716800B2 (es)
KR (3) KR102796051B1 (es)
CN (2) CN111757742B (es)
BR (1) BR112020017661A2 (es)
CA (1) CA3091700A1 (es)
EA (1) EA202092030A1 (es)
MX (2) MX2020008925A (es)
PH (1) PH12020551313B1 (es)
SG (1) SG11202007977RA (es)
TW (3) TWI781296B (es)
UA (1) UA129517C2 (es)
WO (1) WO2019168023A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111757742B (zh) * 2018-02-28 2023-09-26 参天制药株式会社 含有地夸磷索及阳离子性聚合物的眼科用组合物
CN113518646B (zh) * 2019-02-27 2023-12-12 参天制药株式会社 含有地夸磷索或其盐,乙烯基系高分子及纤维素系高分子的眼科用组合物
CN114286670B (zh) * 2019-08-27 2024-01-16 参天制药株式会社 含有地夸磷索或其盐、及聚乙烯吡咯烷酮的水性眼科用组合物
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN113712910A (zh) * 2021-08-05 2021-11-30 广州市桐晖药业有限公司 一种滴眼液及其制备方法
KR102794468B1 (ko) 2022-04-04 2025-04-14 서울대학교산학협력단 감미 억제용 조성물 및 식품의 감미 억제 방법
KR20250038935A (ko) * 2023-09-13 2025-03-20 루다큐어 주식회사 8-옥소-2'-데옥시구아노신 또는 이의 약학적으로 허용가능한 염을 포함하는 수용액 형태의 점안제
KR20250160050A (ko) 2024-05-03 2025-11-11 삼천당제약주식회사 물리화학적 특성이 개선된 안구건조증 예방 또는 치료용 약학 조성물
CN119970633A (zh) * 2025-03-26 2025-05-13 苏州乐珠制药有限公司 一种地夸磷索钠滴眼液及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01294620A (ja) 1988-05-19 1989-11-28 Kissei Pharmaceut Co Ltd 水溶液製剤およびその製造方法
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP3155689B2 (ja) * 1995-08-10 2001-04-16 昭和薬品化工株式会社 消炎点眼剤
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
DK1012154T3 (da) 1997-07-25 2004-07-26 Inspire Pharmaceuticals Inc Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf
JP2001294620A (ja) 2000-04-11 2001-10-23 Showa Denko Kk プラスチックレンズ材料、該材料の製造方法、プラスチックレンズ用組成物、該組成物を硬化してなるプラスチックレンズ、及び該プラスチックレンズの製造方法
EP1428538B1 (en) * 2000-05-30 2013-08-14 Santen Pharmaceutical Co., Ltd Ectocornea extension promoters
WO2006088758A2 (en) * 2005-02-14 2006-08-24 Johnson & Johnson Vision Care, Inc. A comfortable ophthalmic device and methods of its production
JP4515960B2 (ja) 2005-05-19 2010-08-04 株式会社資生堂 整髪料洗浄剤及びその使用方法
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
BRPI0909797A2 (pt) * 2008-03-07 2017-08-22 Sun Pharma Advanced Res Co Ltd Composição oftálmica
MX386162B (es) * 2010-12-28 2025-03-18 Santen Pharmaceutical Co Ltd Solución oftálmica que comprende diquafosol, método para producir la misma, y método para inhibir la formación de precipitado insoluble.
KR101875845B1 (ko) * 2012-03-26 2018-07-06 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 함유 점안액
RS59383B1 (sr) * 2014-05-07 2019-11-29 Croma Pharma Ges M B H Vodeni oftalmološki rastvor i postupak za lečenje sindroma suvog oka
CN106456791B (zh) * 2014-06-10 2021-08-10 日本乐敦制药株式会社 眼科用水性组合物
MX384935B (es) * 2014-12-25 2025-03-14 Santen Pharmaceutical Co Ltd Solucion oftalmica acuosa.
KR101587385B1 (ko) * 2015-07-29 2016-01-21 국제약품공업주식회사 사이클로스포린 함유 무자극성의 안약조성물 및 편리한 제조방법
JP2017043607A (ja) * 2015-08-24 2017-03-02 参天製薬株式会社 眼科用フィルム製剤
LT3266446T (lt) * 2016-07-07 2019-01-25 Laboratorios Salvat, S.A. Oftalmologinė kompozicija, apimanti ricinos aliejų ir vidutinio grandinės ilgio trigliceridą
CN106772747B (zh) * 2016-12-26 2022-10-18 深圳市光科全息技术有限公司 一种光学膜及其制作方法
KR102281853B1 (ko) * 2017-04-25 2021-07-23 와카모토 세이야꾸 가부시끼가이샤 열겔화 인공 누액
JP6582029B2 (ja) * 2017-10-03 2019-09-25 株式会社メニコン 眼科用組成液及びその使用方法
CN111757742B (zh) 2018-02-28 2023-09-26 参天制药株式会社 含有地夸磷索及阳离子性聚合物的眼科用组合物
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
CN113518646B (zh) * 2019-02-27 2023-12-12 参天制药株式会社 含有地夸磷索或其盐,乙烯基系高分子及纤维素系高分子的眼科用组合物
CN114286670B (zh) 2019-08-27 2024-01-16 参天制药株式会社 含有地夸磷索或其盐、及聚乙烯吡咯烷酮的水性眼科用组合物

Also Published As

Publication number Publication date
JP7796782B2 (ja) 2026-01-09
CN117137866A (zh) 2023-12-01
TWI833406B (zh) 2024-02-21
KR20250053220A (ko) 2025-04-21
US20210000844A1 (en) 2021-01-07
UA129517C2 (uk) 2025-05-21
TW202000212A (zh) 2020-01-01
KR102472773B1 (ko) 2022-11-30
CN111757742B (zh) 2023-09-26
CN111757742A (zh) 2020-10-09
JP2024045506A (ja) 2024-04-02
TWI898399B (zh) 2025-09-21
EA202092030A1 (ru) 2020-11-16
PH12020551313B1 (en) 2024-02-28
EP3760207A1 (en) 2021-01-06
KR102796051B1 (ko) 2025-04-14
WO2019168023A1 (ja) 2019-09-06
JP2022136152A (ja) 2022-09-15
TW202306572A (zh) 2023-02-16
JPWO2019168023A1 (ja) 2020-05-28
SG11202007977RA (en) 2020-09-29
KR20200127002A (ko) 2020-11-09
JP2020138980A (ja) 2020-09-03
JP7472202B2 (ja) 2024-04-22
JP6716800B2 (ja) 2020-07-01
CA3091700A1 (en) 2019-09-06
BR112020017661A2 (pt) 2020-12-22
KR20220163519A (ko) 2022-12-09
MX2022014791A (es) 2023-01-16
PH12020551313A1 (en) 2021-09-06
EP3760207A4 (en) 2023-10-04
TWI781296B (zh) 2022-10-21
JP7297718B2 (ja) 2023-06-26
TW202423451A (zh) 2024-06-16

Similar Documents

Publication Publication Date Title
MX2022014791A (es) Composicion oftalmica que comprende dicuafosol y polimero cationico.
MX2020009947A (es) Amidas heterocíclicas útiles como moduladores de proteínas.
EP4035096A4 (en) ARTIFICIAL INTELLIGENCE (AI) DECENTRALIZED MACHINE LEARNING TRAINING SYSTEM
WO2021125069A8 (en) Composition comprising hyaluronic acid-based polyion complex particle
BR0114561A (pt) Derivados amida reticulados do acido hialurÈnico e método de produção dos mesmos
BR112018070323A2 (pt) vacina contra rsv
MA50746A (fr) Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
WO2016183495A3 (en) Devices for occlusion of an atrial appendage
BR112019000178A2 (pt) hidrogéis de silicone compreendendo n-alquil metacrilamidas e lentes de contato produzidas a partir dos mesmos
MXPA02012601A (es) Polimeros radicales cationicos o anfotericos autoadhesivos y su uso en cosmeticos.
SG11201810727SA (en) Elastomer
MX2021002665A (es) Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas.
EP3721816A3 (en) Improved tissue fixation devices
IL270858B (en) Scanning jig and method and system for specifying spatial position of implant
WO2016113550A3 (en) Dressing
EP3512239A4 (en) USER TERMINAL AND RADIO COMMUNICATION METHOD
DE602004024825D1 (de) Geräte zur veränderung der relativen krümmung des felds und der positionen von peripheren achsenverschobenen fokalpositionen
RU2014109981A (ru) Способ и устройство для инкапсулирования жесткой вставки в контактную линзу с целью коррекции астигматизма у пациентов
EP3747676A4 (en) PROCEDURE, DEVICE AND TERMINAL FOR IDENTIFIER CONFIGURATION
BR112018072343A2 (pt) método de determinação de um filtro para uma lente oftálmica em função de uma grandeza representativa de uma sensibilidade dinâmica do olho de um portador a uma variação de um fluxo luminoso
BR112017018491A2 (pt) hidrolisados de proteína à base de leite e composições produzidas a partir dos mesmos
SG10201705219QA (en) Preparation of N,N-(di)alkylaminoalkyl(meth)acrylamide or N,N-(di)alkylaminoalkyl (meth)acrylate and the quaternary ammonium salts thereof as flocculating aids and gelling agents
EP4082491A4 (en) IMPLANT DELIVERY SYSTEM
EP3765095A4 (en) OPHTHALMIC COMPOSITIONS OF INDIGO-CARMINE AND EYEPIECES USES THEREOF
EP3721828A4 (en) FIXATION OF A DENTAL IMPLANT